Table 1. Combination index of metformin and erlotinib treatment.
| Synergistic (CI) | Additive (CI) | Antagonistic (CI) |
|---|---|---|
| MDA-MB-468* (0.44) | MX-1* (1.19) | HCC-1187 (1.79) |
| MCF7 (0.46) | HCC-1143 (0.97) | HCC-38* (49.8) |
| MDA-MB-435S (0.27) | BT-549* (1.00) | MDA-MB-157 (2.04) |
| BT-20 (0.56) | SUM-149* (0.82) | MDA-MB-231 (15.4) |
| HCC-1937* (0.61) | HCC-1806 (1.25) | |
| HCC-70* (0.21) | ||
| L56Br-C1 (0.57) | ||
| MDA-MB-436* (0.36) |
17 cell lines were treated with metformin and erlotinib as well as their combinations at various doses (6 replicates per treatment) and combination indices (CI) at metformin dose of 2 mM and erlotinib dose of 4 μM were determined using the software Compusyn. PTEN mutant lines are marked with (*)